HB 1638: creating a bypass mechanism for health insurer step therapy protocols when medically necessary.
HB 1638 status: Hearing Scheduled — Public Hearing: 02/17/2026 11:00 am GP 159 (updated Aug 5, 2026).
What this bill does
Overall score
Bill summary
OfficialRight now, insurance companies often force you to try cheaper drugs before they will pay for the one your doctor actually prescribed. This bill would create a way to skip that rule when a doctor decides you medically need a specific treatment. It is currently being debated in the House.
Key analysis
Impact analysis
Environment
Benefits
- none identified
Risks
- none identified
Economy
Benefits
- may improve workforce productivity through better patient health
Risks
- potential for increased health insurance premiums due to higher medication costs
- increased administrative costs for health carriers
Society
Benefits
- establishes clear, timely paths for patients to bypass restrictive therapy protocols
- protects patients with metastatic cancer from mandatory step therapy
- ensures coverage continuity for patients already stabilized on effective medications
Risks
- potential for delayed care if override request processes are not efficiently implemented
How trustworthy & consequential it is
Source
LegiScan
Confidence
highhigh
Analysis status
LegiScan full bill text
Increased administrative overhead for health carriers may lead to premium adjustments
Fiscal impact on private insurance premiums is indeterminable according to the insurance department
Where it stands
Introduced
CompleteCommittee
CurrentPublic Hearing: 02/17/2026 11:00 am GP 159
Floor
UpcomingGovernor
UpcomingEnacted
UpcomingHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.